AstraZeneca PLC (AZN)vsCorcept Therapeutics Incorporated (CORT)
AZN
AstraZeneca PLC
$160.17
+0.33%
HEALTHCARE · Cap: $252.33B
CORT
Corcept Therapeutics Incorporated
$112.79
-1.85%
HEALTHCARE · Cap: $12.32B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 7286% more annual revenue ($61.37B vs $830.81M). AZN leads profitability with a 17.0% profit margin vs 6.6%. CORT appears more attractively valued with a PEG of 0.81. CORT earns a higher WallStSmart Score of 60/100 (C+).
AZN
Buy60
out of 100
Grade: C+
CORT
Buy60
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+18.4%
Fair Value
$196.10
Current Price
$160.17
$35.93 discount
Intrinsic value data unavailable for CORT.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 21 in profit
Strong operational efficiency at 23.5%
Generating 2.1B in free cash flow
Revenue surging 31.7% year-over-year
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Growing faster than its price suggests
Earnings expanding 24.1% YoY
Areas to Watch
2.5% earnings growth
Distress zone — elevated risk
Trading at 17.2x book value
ROE of 7.8% — below average capital efficiency
6.6% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.0% and operating margin at 23.5%. PEG of 1.28 suggests the stock is reasonably priced for its growth.
Bull Case : CORT
The strongest argument for CORT centers on Revenue Growth, Debt/Equity, Altman Z-Score. Revenue growth of 31.7% demonstrates continued momentum. PEG of 0.81 suggests the stock is reasonably priced for its growth.
Bear Case : AZN
The primary concerns for AZN are EPS Growth, Altman Z-Score.
Bear Case : CORT
The primary concerns for CORT are Price/Book, Return on Equity, Profit Margin. A P/E of 253.3x leaves little room for execution misses.
Key Dynamics to Monitor
AZN profiles as a mature stock while CORT is a hypergrowth play — different risk/reward profiles.
CORT carries more volatility with a beta of 0.45 — expect wider price swings.
CORT is growing revenue faster at 31.7% — sustainability is the question.
AZN generates stronger free cash flow (2.1B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (60/100 vs 60/100), backed by strong 17.0% margins. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Corcept Therapeutics Incorporated
HEALTHCARE · BIOTECHNOLOGY · USA
Corcept Therapeutics Incorporated discovers, develops, and markets drugs for the treatment of severe metabolic, cancer, and psychiatric disorders in the United States. The company is headquartered in Menlo Park, California.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?